Organobalance sells yeast strain to Sanofi
Berlin/Paris – Sanofi Pasteur has licensed a yeast strain from German Organobalance to produce vaccines. With the deal, the vaccines division of the French drugmaker will gain exclusive access to a modified strain of "Saccharomyces cerevisiae. "We are delighted to have made this agreement with Sanofi Pasteur, a partner who will make commercial use of our research findings on an industrial scale", said Christine Lang, CEO of the specialist company for microbiological strain development based in Berlin. In the past, Organobalance has been mainly known for its comprehensive library of strains of lactic acid bacteria. The deal with Sanofi highlights another business area, the metabolic engineering of yeast strains. "This part of what we are doing has not been known very widely", said Klaus Pellengahr, director of business development. "That's why I'm quite happy about this deal with a well known and substantial partner like Sanofi." Organobalance was set up in 2001 with the aim to develop the health-promoting effects of lactic acid bacteria for new applications.